

## Reactive Oxygen Species as Mediators of Tissue Protection and Injury

V BAUER<sup>1</sup> AND F BAUER<sup>2</sup>

*1 Institute of Experimental Pharmacology, Slovak Academy of Sciences, Bratislava, Slovakia*

*2 Department of Neonatology District Hospital, Nove Zamky, Slovakia*

**Abstract.** Extensive research efforts during the last three decades resulted in a large body of experimental evidence that suggests an important role of the disbalance between generation and elimination of the oxygen and xenobiotic derived free radicals in physiological and pathological processes. Reactive oxygen species (ROS) are generated in many metabolic pathways, and are entering the organisms from exogenous sources, dominantly via airways and gut. ROS induced injuries, e.g. thermal, chemical, radiation, ischaemia/reperfusion, inflammation, hyperoxia, etc., result in diseases like atherosclerosis, ulcerative colitis, autoimmune diseases, asthma, etc. The current paper is designed to provide an overview of the effects ROS may exert in various tissues. Because of the effective defense systems, the tolerance of viable human cells to ROS is relatively high. The oxidant stress induced dysfunction of various systems, such as the gut, airways, nervous, cardiovascular system, etc., involve both direct and indirect mechanisms. Understanding of these molecular mechanisms is essential for a rational antioxidant therapy.

**Key words:** Reactive oxygen species, sources — Tissue targets — Diseases — Therapeutic approaches

### Introduction

The possibility that O<sub>2</sub> might be toxic was recognized by Joseph Priestley as early as in 1775 when he found this molecule. Nevertheless, it was only the discovery of the existence of superoxide dismutase (SOD) activity in mammalian cells (McCord and Fridovich 1969) and the association of the bactericidal activity of neutrophils with the production of the superoxide radical (O<sub>2</sub><sup>•-</sup>) (Babior et al. 1976) that, linked free radicals to numerous physiological and pathophysiological processes.

The prevalence of O<sub>2</sub> in biological systems means that oxygen centred radicals are found most commonly. The terms reduced oxygen species, reactive oxygen

---

Correspondence to Prof. Viktor Bauer, M.D., D.Sc., Institute of Experimental Pharmacology, Slovak Academy of Sciences, Dubravská cesta 9, 842 16 Bratislava, Slovakia  
E-mail: exfabauv@savba.sk

metabolites, reactive oxygen intermediates (ROI) or reactive oxygen species (ROS) are now generally preferred because except  $O_2^{\cdot-}$  and hydroxyl radical ( $\cdot OH$ ), the other forms, i.e. singlet oxygen ( $^1O_2$ ), hydrogen peroxide ( $H_2O_2$ ), hypochlorous acid (HOCl), peroxide, hydroperoxide and epoxide metabolites of endogenous lipids and xenobiotics have chemically reactive oxygen containing functional groups but they are not radicals and do not necessarily interact with tissues via radical reactions.

### Cellular sources of ROS

In processes that are central to metabolism in aerobic life,  $O_2$  acts as a terminal electron acceptor. Approximately 90% of all oxygen consumed by mammalian cells is catalytically reduced by four electrons to yield two molecules of water. Transfer of one electron to  $O_2$  yields  $O_2^{\cdot-}$ , which is rapidly dismutated by SOD to  $H_2O_2$ . Further reactions require either transition metals to form the extremely reactive  $\cdot OH$  or myeloperoxidase to produce HOCl and  $^1O_2$ . Nitric oxide (NO), generated by the endothelium, macrophages, etc., can react with  $O_2^{\cdot-}$  to form peroxyntirite ( $OONO^{\cdot-}$ ), which after protonation is unstable and decomposes to  $\cdot OH$  or nitrogen dioxide ( $NO_2$ ). ROS found in mammalian tissues are of endogenous (e.g. phagocytes, respiratory chain in mitochondria, enzymatic reactions) and exogenous origin (e.g. radiation, air pollution, cigarette smoke, xenobiotics, drugs) (Fig. 1). They are essential for normal function or metabolism of the majority of mammalian cells. ROS are produced in cell membrane lipid bilayers, in the electron transport system in mitochondria, in cell organelles, like peroxisomes, lysosomes, endoplasmic reticulum, as well as in the cytoplasm by enzymatic and non-enzymatic reactions (Tab. 1).

Reactive oxygen species are destructive unless tightly controlled. Mammalian cells have developed a battery of defenses (catalytic, scavenging, antioxidant, chelating reactions) to prevent and repair the injuries caused by oxidative stress. These


















Figure 1. Reactive oxygen species and their sources in the mammalian organism.

Table. 1. Enzymatic and nonenzymatic sources of reactive oxygen species

**a. Enzymatic****Xanthine oxidase****NADPH oxidase****Amine oxidases****Peroxidases**


H

**Hypohalous acid formation****NADH oxidase reaction****Aldehyde oxidase****Dihydroorotate dehydrogenase****b. Nonenzymatic****Reduced flavin****Coenzyme**

include catalytic ROS removal by enzymes, such as SOD (cytosolic, mitochondrial), catalase (cytosolic, peroxisomal), glutathion peroxidase (cytosolic, mitochondrial), removal of transition metals by endogenous chelators (e.g. ferritin, ceruloplasmin, serum albumin), and the nonenzymatic quenching or scavenging of ROS by antioxidants, involving cholesterol,  $\alpha$ -tocopherol, ascorbic acid,  $\beta$ -carotene, and thiol-containing compounds. Recently it has been speculated that uric acid, melatonin, glucose and bilirubin may be physiologically important as antioxidants as early as in the first week of life (Bervoets et al. 1994; Schrod et al. 1997). Since the above mentioned enzymes are only in trace amounts in the extracellular space, ROS production in the interstitium may have a harmful effect on the surrounding living cells.

**Biological targets of ROS**

The toxicity of many xenobiotics is now associated with formation of free radicals, which may be involved in different pathologic conditions. ROS act either extracellularly (e.g. inflammatory reactions, cataractogenesis, atherosclerosis), intracellularly (e.g. ageing, ischaemia-reperfusion, cancer) or both (e.g. immune reactions, xenobiotic induced reactions, senile dementia). As a consequence of having one or more unpaired electrons in outer orbital, ROS have an increased reactivity with other molecules in a variety of biological systems. These species produce damage of lipids, proteins and DNA (Fig. 2). The developed membrane impairments, altered gene expressions, and accumulation of intracellular free  $\text{Ca}^{2+}$  result in activation/deactivation of various enzymes and lead to cell injury or death.



**Figure 2.** Mechanism of reactive oxygen species induced cell injury

### Clinical conditions associated with ROS production induced tissue damage

There is a consensus that free radicals are definitely responsible for oxygen toxicity and tetrachlormethane induced liver damage. In the perinatal period, the fetus and newborn, and especially premature infants are more exposed to oxidative injury than adults (e.g. oxygen-, photo-, NO-therapy), and are particularly susceptible to free radical injury because of a relative deficiency in endogenous antioxidants (Inder et al 1994, Robbins et al 1995). Recent clinical and experimental evidence suggests that oxygen toxicity arising from disbalance between production and elimination of ROS is a major factor in the pathogenesis of life-threatening complications of toxicity of xenobiotics, drugs and participates in the development of diseases of various tissues and systems not only in very low birth weight infants but also in adults.

There are different pathologic conditions where ROS are at least partially involved in the pathophysiological mechanisms. Granger et al (1981) introduced a hypothesis on the role of ROS in reperfusion injury after intestinal ischaemia. ROS affect the gut, airways and vessels either directly or indirectly via their innervation, epithelium or endothelium (Van der Vliet et al 1989, Bauer et al 1997). The epithelium and endothelium, which are the most vulnerable components of smooth muscle tissues, are frequently exposed to ROS of both exogenous (ozone, nitrogen oxides, different particles, etc.) and endogenous origin (inflammatory cells, peroxisomes, metabolites of xenobiotics, etc.). An intact epithelium or endothelium is

generally sufficient to protect the smooth muscle from ROS-induced spasms. In the presence of injury, however, ROS can produce prolonged smooth muscle contractions or motility disturbances. Several pathological conditions of the digestive system (e.g. ischaemia-reperfusion injury, inflammation, Crohn's disease, ulcerative colitis, ulcer disease, xenobiotic- and drug-related diseases) are characterised by the formation of ROS (Parks et al. 1983; Mansbach et al. 1986; Suematsu et al. 1987; Ramage et al. 1988; Van der Vliet et al. 1989; Nilsson et al. 1994; Papparella et al. 1997). Conditions in which the function of the smooth muscle is affected involve also injuries and diseases of the airways, such as normobaric hyperoxic injury, bronchial hyperreactivity, respiratory distress syndromes (ARDS, NRDS), bronchopulmonary dysplasia, idiopathic pulmonary fibrosis, emphysema, asthma, diseases induced by inhalation of pollutants, xenobiotic-related diseases, pulmonary hypertension, etc. (Evans et al. 1986; Mathru et al. 1994; Plaza et al. 1995; Bracci 1997). The heart, vessels and their endothelium, as well as the epicardium, are also targets of ROS (e.g. ischaemia-reperfusion injury after infarction or transplantation, effects of chemicals as ethanol or doxorubicin, xenobiotic-related diseases, atherosclerosis and hypertension, selenium deficiency, vasculitis). Due to their action, the vascular resistance and tone of the vessel wall is significantly affected (Rubanyi 1988; Wolin 1991; Bharadwaj and Prasad 1997). Several diseases of the brain (hyperbaric hyperoxic injury, hypoxic ischaemic encephalopathy of infants, Parkinson's disease, effect of neurotoxins, vitamin E deficiency, neuronal lipofuscinoses, traumatic injury, inflammation, ischemia-reperfusion, Alzheimer's disease), of blood (effects of chemicals as phenylhydrazine, primaquine, sulphonamides, or lead, protoporphyrine photooxidation, malaria, anaemias – sickle cell or favism), the liver (ischaemia-reperfusion, effects of halogenated hydrocarbons, quinones, iron, acetaminophen, ethanol, or endotoxins), the kidney (autoimmune nephrosis, inflammation, effects of aminoglycosides or heavy metals), the eye (prematurity-, diabetic-, photic-retinopathy, cataracts), the skin (solar or ionizing radiation, thermal injury, effects of photosensitisers as tetracyclines, contact dermatitis, porphyria), of the striated muscle (muscular dystrophy, multiple sclerosis, exercise), and others (ageing, age-related diseases, cancer, rheumatoid arthritis and other autoimmune diseases as lupus erythematoses, inflammation in general, developmental toxicity, alloxan-induced diabetes, effects of radiation, radiosensitizers, iron overload) are thought to be related to the action of ROS. Direct action of ROS on various tissues is aggravated by modification of the local circulation, which may participate in tissue injuries such as myocardial reperfusion injury of infants and adults or it may participate in pathological processes accompanying ageing, diabetes, etc. (Kehrer 1993; Stohs 1995; Fantel 1996).

### **Potential therapeutic approaches**

During the last 25 to 30 years, a large body of experimental evidence has accumulated from pharmacological intervention studies suggestive of the important role exerted by ROS in mammalian tissues under normal and pathological conditions.

The drugs which may potentially be used in antioxidant therapy have different chemical structures and mechanisms of action. They are inhibitors of the synthesis of ROS (e.g. allopurinol), agents supporting and complementing enzymatic protective systems used in substitutive therapy (e.g. SOD), antioxidant substances containing thiol groups (e.g. glutathion), vitamins (e.g. A, C, E), drugs interfering with iron and copper metabolism (e.g. desferoxamine), and scavengers of  $O_2^{\cdot-}$  (e.g. flavonoids), of  $\cdot OH$  (e.g. manitol) and substances which eliminate  $H_2O_2$  (e.g. N-acetylcysteine). Inhibition of  $O_2^{\cdot-}$  formation by captopril and nitrosopine and elimination of  $\cdot OH$  by thiourea protects the endothelium of the rat aorta from the deleterious effect of the  $\cdot OH$  produced by  $FeSO_4$  and  $H_2O_2$ . It is well known that the oxidatively modified LDL plays a prominent role in endothelial damage and development of atherosclerosis. The illuminated nifedipine, called nitrosopine, which is void of  $Ca^{2+}$  channel blocking properties, acts as a ROS scavenger. In contrast to nifedipine, it significantly antagonizes the oxidized LDL-induced lipid peroxidation and attenuation of acetylcholine-induced relaxation. Many natural antioxidants, like Kampo Medicines, bisbenzylisoquinoline alkaloids from *Mahonia Aquifolium*, etc. are not only potent inhibitors of lipid peroxidation but also protect acetylcholine induced relaxation of the rat aorta from the deleterious action of ROS (Sotniková et al. 1994; Bauer et al. 1999). Thus our own results also indicate that SOD, catalase, dimethyl-sulfoxide, ascorbic acid, stobadine, nitrosopine, bisbenzylisoquinolines, Kampo Medicines, ACE inhibitors, etc. appear to be useful and promising antioxidants.

Though the first trial of the efficacy of  $\alpha$ -tocopherol in the prevention of  $O_2$  toxicity in preterm newborns was performed in 1949, the clinical efficacy of antioxidants in neonatology has remained a controversial issue. Several of them, e.g. allopurinol,  $\alpha$ -tocopherol, SOD, catalase, propentofylline, deferoxamine, indomethacine, D-penicillamine, were investigated at least in part successfully in preterm or term animals and infants to determine their ability to prevent complications of neonatal intensive care, which may be associated with oxidative injury (e.g. Oroszlán et al. 1992; Palmer et al. 1994; Papparella et al. 1997; Penn et al. 1997; Numagami et al. 1998). The therapeutic relevance of antioxidant therapy varies in different diseases and pathological conditions. There are promising results in some (ischaemic injuries, LDL oxidation, platelet aggregation, pulmonary injuries, central nervous system injuries, ulcerative colitis, chemical poisonings and oxygen stress) (Rice-Evans and Diplock 1993; Hall 1997; Evans et al. 1998), and conflicting results in others, such as bronchial asthma, rheumatic arthritis, cancer, cerebral vasospasms, etc.

Our present knowledge suggests that the toxic effects of ROS may be either the sole cause of tissue injury, partially involved in the pathological mechanisms of diseases, or they may accumulate only as a phenomenon accompanying the pathologic processes.

**Acknowledgements.** This work was supported in part by the Slovak Grant Agency GAV No. 5305 and 6024.

## References

- Babior B M , Curnette J T , McMurick, B J (1976) The particulate superoxide-forming system from human neutrophils properties of the system and further evidence supporting its participation in the respiratory burst *J Clin Invest* **58**, 989-996
- Bauer V , Oike M , Tanaka H , Inoue R , Ito Y (1997) Hydrogen peroxide induced responses of cat tracheal smooth muscle cells *Brit J Pharmacol* **12**, 867-874
- Bauer V , Sotníková R , Machová J , Mátyás S , Pucovský V , Štefek M (1999) Reactive oxygen species as mediators of gut, airway and vessel injury and disease and their pharmacology *Life Sci* **18/19**, 1909-1917
- Bervoets K , Schlenzig J S , Bohles H (1994) Bilirubin in the early neonatal period Is there a positive aspect of hyperbilirubinemia? A medical hypothesis *Fortschr Med* **112**, 192-194
- Bharadwaj L A , Prasad K (1997) Mechanism of hydroxyl radical-induced modulation of vascular tone *Free Radical Biol Med* **22**, 381-390
- Bracci R (1997) Free oxygen radicals and surfactant *Biol Neonate* **71**(Suppl1), 23-27
- Evans H E , Rosenfeld W , Jhaveri R , Concepcion L , Zabaleta I (1986) Oxidant-mediated lung disease in newborn infants *J Free Radical Biol Med* **2**, 369-372
- Evans R V , Shaten B J , Day B W , Kuller L H (1998) Prospective association between lipid soluble antioxidants and coronary heart disease in men The multiple risk factor intervention trial *Amer J Epidemiol* **147**, 180-186
- Fantel A G (1996) Reactive oxygen species in developmental toxicity Review and hypothesis *Teratology* **53**, 196-217
- Granger D N , Rutih G , McCord J M (1981) Role of superoxide radicals in intestinal ischemia *Gastroenterology* **81**, 22-29
- Hall E D (1997) Brain attack Acute therapeutic interventions Free radical scavengers and antioxidants *Neurosurg Clin N Am* **8**, 195-206
- Inder T E , Graham P , Sanderson K , Taylor B J (1994) Lipid peroxidation as a measure of oxygen free radical damage in the VLBW infant *Arch Dis Child Fetal Neonatal* **70**, F107- 111
- Kehrer J P (1993) Free radicals as mediators of tissue injury and disease *Crit Rev Toxicol* **23**, 21-48
- Mansbach C M , Rosen G M , Rahn C A , Strauss K E (1986) Detection of free radicals as a consequence of rat intestinal cellular drug metabolism *Biochim Biophys Acta* **888**, 1-9
- Mathru M , Rooney M W , Dries D J , Hirsch L J , Barnes L , Tobin M J (1994) Urine hydrogen peroxide during adult respiratory distress syndrome in patients with and without sepsis *Chest* **105**, 232-236
- McCord J M , Fridovich I (1969) Superoxide dismutase An enzymatic function for erythrocyte (Hemocuprein) *J Biol Chem* **214**, 6049-6055
- Nilsson U A , Schoenberg H M , Aneman A , Poch B , Magadum S , Beger H G , Lundren O (1994) Free radicals and pathogenesis during ischemia and reperfusion of the cat small intestine *Gastroenterology* **106**, 629-636
- Numagami Y , Marro P J , Mishra O P , Delhoria Papadopoulos M (1998) Effect of propentofylline on free-radical generation during cerebral hypoxia in the newborn piglet *Neuroscience* **84**, 1127-1133
- Oroszlán G , Sanderud J , Saugstad O D , Lakatos L (1992) D-penicillamine old drug, new indication? *Orv Hetil* **133**, 2835-2836
- Palmer C , Roberts R L , Bero C (1994) Deferoxamine posttreatment reduces ischemic brain injury in neonatal rats *Stroke* **25**, 1039-1045

- Papparella A , DeLuca F G , Oyer C E , Pinar H , Stonestreet B S (1997) Ischemia-reperfusion injury in the intestines of newborn, *Pediat Res* **42**, 180-188
- Parks D A , Bulkley G B , Granger D N (1983) Role of oxygen derived free radicals in digestive tract diseases *Surgery* **94**, 415-422
- Penn J S , Tolman B L , Bullard L E (1997) Effect of a water-soluble vitamin-analog of retinopathy of prematurity *Free Radical Biol Med* **22**, 977-984
- Plaza V , Prat J , Roselló J , Ballester E , Ramis I , Mullol J , Gelpi E , Vives-Corróns J L L , Picado C (1995) In vitro release of arachidonic acid metabolites, glutathione peroxidase, and oxygen-free radicals from platelets of asthmatic patients with and without aspirin intolerance *Thorax* **50**, 490-496
- Ramage J K , Hunt R H , Perdue M H (1988) Changes in intestinal permeability and epithelial differentiation during inflammation of the rat *Gut* **29**, 57-61
- Rice-Evans C A , Diplock A T (1993) Current status of antioxidant therapy *Free Radical Biol Med* **15**, 77-96
- Robbins C G , Davis J M , Merritt T A , Amirghamian J D , Sahgal N , Morin F C 3<sup>rd</sup> , Horowitz S (1995) Combined effects of nitric-oxide and hyperoxia on surfactant function and pulmonary inflammation *Amer J Physiol* **13**, 545-550
- Rubanyı G M (1988) Vascular effects of oxygen-derived free radicals *Free Rad Biol Med* **4**, 107-120
- Schrod L , Neuhaus T , Speer C P , Girschick H (1997) Possible role of uric acid as an antioxidant in premature infants *Biol Neonate*, **72**, 102-111
- Sotníková R , Košťálová D , Vaverková Š (1994) Effect of bisbenzylisoquinoline alkaloids from *Mahonia Aquifolium* on the isolated rat aorta *Gen Pharmacol* **25**, 1405-1410
- Stohs S J (1995) The role of free radicals in toxicity and disease *J Basic Clin Physiol Pharmacol* **6**, 205-228
- Suematsu M , Suzuki M , Miura S , Nagata H , Oshio C , Asakura H , Watanabe M , Tsuchiya M (1987) Sulfasalazine and its metabolites attenuate respiratory burst of leukocytes - a possible mechanism of anti-inflammatory effects *J Clin Lab Immunol* **23**, 31-33
- Van der Vliet A , Tunstara T J R , Bast A (1989) Modulation of oxidative stress in gastrointestinal tract and effect on rat intestinal motility *Biochem Pharmacol* **38**, 2807-2818
- Wolin M S (1991) Activated oxygen metabolites as regulators of vascular tone *Klin Wochenschr* **69**, 1046-1049